RDY DR REDDYS LABORATORIES LTD IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1135951 · Reporting currency INR · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: INR | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY2022*2022-03-31 | FY2021*2021-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 325.54B | 279.16B | 245.88B | 214.39B | 189.72B |
| Cost of revenue | 135.11B | 115.56B | 106.54B | 100.55B | 86.64B |
| Gross profit | 190.43B | 163.61B | 139.34B | 113.84B | 103.08B |
| R&D expense | 27.38B | 22.87B | 19.38B | 17.48B | 16.54B |
| SG&A expense | 93.87B | 77.20B | 68.03B | 62.08B | 54.65B |
| Operating income | 71.84B | 67.73B | 57.14B | 29.48B | 24.28B |
| Interest expense | 2.83B | 1.71B | 1.43B | 958.00M | 970.00M |
| Pretax income | 76.78B | 71.87B | 60.37B | 32.30B | 26.41B |
| Income tax | 19.54B | 16.19B | 15.30B | 8.73B | 9.18B |
| Net income | 56.54B | 55.68B | 45.07B | 23.57B | 17.24B |
| EBITDA | 88.90B | 82.57B | 69.78B | 41.30B | 37.08B |
| EPS (basic) | 67.88 | 66.93 | 54.28 | 142.08 | 103.94 |
| EPS (diluted) | 67.78 | 66.80 | 54.17 | 141.69 | 103.65 |
| Dividends declared per share | 40.00 | 40.00 | 30.00 | 25.00 | 25.00 |
| Weighted avg. shares (diluted) | 834.18M | 833.54M | 831.94M | 166.34M | 166.32M |
| Banking | |||||
| Net interest income | -152.00M | 567.00M | -248.00M | 7.00M | -144.00M |
| Balance sheet | |||||
| Cash & equivalents | 14.65B | 7.11B | 5.78B | 14.85B | 14.83B |
| Short-term investments | 43.25B | 74.36B | 56.02B | 29.51B | 19.74B |
| Receivables | 90.42B | 80.30B | 72.48B | 66.76B | 49.64B |
| Inventory | 71.08B | 63.55B | 48.67B | 50.88B | 45.41B |
| Current assets | 250.11B | 248.05B | 204.25B | 181.86B | 148.25B |
| PP&E, netmay include right-of-use assets (IFRS) | 97.76B | 76.89B | 66.46B | 62.17B | 57.11B |
| Goodwill | 11.81B | 4.25B | 4.25B | 4.42B | 4.57B |
| Intangibles | 96.80B | 36.95B | 30.85B | 27.25B | 35.65B |
| Total assets | 492.99B | 387.52B | 321.85B | 292.83B | 265.49B |
| Current liabilities | 130.39B | 96.04B | 85.84B | 94.02B | 83.39B |
| Short-term debt | 38.05B | 12.72B | 7.39B | 27.08B | 23.14B |
| Long-term debt | 7.86B | 5.99B | 1.28B | 5.75B | 6.30B |
| Total debt | 45.91B | 18.71B | 8.67B | 32.83B | 29.43B |
| Total liabilities | 155.82B | 106.97B | 90.86B | 102.30B | 92.43B |
| Shareholders' equity | 333.39B | 280.55B | 230.99B | 190.53B | 173.06B |
| Net debt | 31.25B | 11.61B | 2.89B | 17.98B | 14.61B |
| Shares outstanding | 832.64M | 830.78M | 829.79M | 165.73M | 165.78M |
| Cash flow statement | |||||
| Operating cash flow | 46.43B | 45.43B | 58.88B | 28.11B | 35.70B |
| Capital expenditure | 27.50B | 16.40B | 11.32B | 14.66B | 9.74B |
| Free cash flow | 18.92B | 29.03B | 47.55B | 13.45B | 25.96B |
| Investing cash flow | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B |
| Financing cash flow | 18.91B | -3.76B | -26.86B | -2.42B | -298.00M |
| Depreciation & amortization | 17.06B | 14.84B | 12.64B | 11.82B | 12.80B |
| Stock-based compensation | 424.00M | 407.00M | 397.00M | 592.00M | 584.00M |
| Dividends paid | 6.66B | 6.65B | 4.98B | 4.15B | 4.15B |
| Share buybacks | — | — | — | 0 | 1.19B |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, INR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.